Abstract
CX516, a positive modulator of the glutamatergic alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor, improves performance in tasks requiring learning and memory in animals. CX516 was added to clozapine in 4-week, placebo-controlled, dose-finding (N = 6) and fixed-dose (N = 13) trials. CX516 was tolerated well and was associated with moderate to large, between-group effect sizes compared with placebo, representing improvement in measures of attention and memory. These preliminary results suggest that CX516 and other "ampakines" hold promise for the treatment of schizophrenia.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antipsychotic Agents / administration & dosage
-
Antipsychotic Agents / therapeutic use*
-
Attention / drug effects
-
Clozapine / administration & dosage
-
Clozapine / therapeutic use*
-
Cognition / drug effects
-
Dioxoles / administration & dosage
-
Dioxoles / therapeutic use*
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Drug Therapy, Combination
-
Female
-
Humans
-
Male
-
Memory / drug effects
-
Middle Aged
-
Pilot Projects
-
Piperidines / administration & dosage
-
Piperidines / therapeutic use*
-
Psychological Tests
-
Schizophrenia / drug therapy*
Substances
-
1-(quinoxalin-6-ylcarbonyl)piperidine
-
Antipsychotic Agents
-
Dioxoles
-
Piperidines
-
Clozapine